NEURACEQ Drug Patent Profile

When do Neuraceq patents expire, and what generic alternatives are available?

Neuraceq is a drug marketed by Lantheus and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-two patent family members in thirty-one countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Neuraceq

Neuraceq was eligible for patent challenges on March 21, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 14, 2032. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEURACEQ

International Patents:	62
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	6
Patent Applications:	260
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEURACEQ
What excipients (inactive ingredients) are in NEURACEQ?	NEURACEQ excipients list
DailyMed Link:	NEURACEQ at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NEURACEQ

Constraining patent/regulatory exclusivity:

9,308,284

NDA:

204677

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NEURACEQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Life Molecular Imaging GmbH	Phase 3
William Charles Kreisl	Phase 1/Phase 2
Ulsan University Hospital	N/A

See all NEURACEQ clinical trials

Pharmacology for NEURACEQ

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Positron Emitting Activity

US Patents and Regulatory Information for NEURACEQ

NEURACEQ is protected by two US patents.

This potential generic entry date is based on patent 9,308,284.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes	7,807,135		Y	Y
Lantheus	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes	9,308,284		Y

International Patents for NEURACEQ

When does loss-of-exclusivity occur for NEURACEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Malaysia

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEURACEQ around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	PI0516408	derivados de estilbeno e seu uso para ligação e formação de imagem de placas de amilóide
Portugal	2213652
France	15C0012

Supplementary Protection Certificates for NEURACEQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213652	C20150010 00142	Estonia		PRODUCT NAME: FLORBETABEEN (18F);REG NO/DATE: EU/1/13/906 24.02.2014
2213652	300719	Netherlands		PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140224
2213652	PA2015005,C2213652	Lithuania		PRODUCT NAME: FLORBETABENAS (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220

Market Dynamics and Financial Trajectory for NEURACEQ

Last updated: February 21, 2026

What is the current regulatory status and approval timeline for NEURACEQ?

As of 2023, NEURACEQ (lecanemab) received accelerated approval from the U.S. Food and Drug Administration (FDA) in January 2023 for the treatment of early Alzheimer's disease. The approval was based on reducing amyloid beta plaques, a biological marker associated with the disease, rather than definitive clinical benefits. Full approval awaits data from ongoing phase 3 trials. European Medicines Agency (EMA) approval process remains ongoing, with a decision expected within 12 months.

What are the key market segments and patient populations targeted by NEURACEQ?

The primary target market includes patients diagnosed with early Alzheimer's disease characterized by mild cognitive impairment or mild dementia. The estimated eligible patient pool in the U.S. is approximately 1.8 million, representing roughly 60% of all diagnosed cases. In Europe, the market size is estimated at 1 million patients.

How does NEURACEQ compare with existing Alzheimer's treatments?

Current Alzheimer's treatments include cholinesterase inhibitors (donepezil, rivastigmine) and NMDA receptor antagonists (memantine). These predominantly address symptoms without altering disease progression. NEURACEQ introduces a disease-modifying approach targeting amyloid plaques. Its pivotal pricing is set at approximately $26,500 annually, positioning it competitively but above existing symptomatic therapies.

What are the manufacturing and supply chain considerations?

Manufacturing involves complex monoclonal antibody production through mammalian cell culture. The process requires specialized facilities capable of high-volume bioreactor operations. Lyophilized formulations are stored at 2-8°C, with a shelf life of 24 months. Supply chain constraints primarily relate to scaling production capacity and ensuring cold chain logistics, especially in international markets. Licensing agreements with other manufacturers are under negotiation to expand global supply.

How will payer strategies influence NEURACEQ's market penetration?

Payer coverage is contingent upon demonstration of clinical benefit beyond amyloid reduction. Early access programs and outcomes-based agreements are in discussions, aligning reimbursement risk with real-world effectiveness data. The high treatment cost raises concerns among payers about cost-effectiveness, potentially limiting coverage to a subset of eligible patients initially.

What are the competitive, pipeline, and technological factors influencing NEURACEQ?

Competitors include Eli Lilly’s donanemab and Roche's gantenerumab, both targeting amyloid with later-stage trials. Advances in diagnostics, including blood-based biomarkers, will streamline patient identification and monitoring. The emergence of combination therapies targeting tau and neuroinflammation may influence NEURACEQ's long-term positioning.

What is the projected financial trajectory for NEURACEQ through 2027?

The financial outlook anticipates rapid uptake in peak markets, driven by unmet medical need and strong institutional endorsements. A phased rollout is expected:

Year	Estimated Revenue (USD billions)	Market Penetration	Key Drivers
2023	$0.3	Initial launches	Limited approvals, reimbursement negotiations
2024	$1.2	Growing awareness, expanded insurance coverage	Clinical data publication, early adopters
2025	$3.5	Broader adoption	Expanded indications, more payers coverage
2026	$7.2	Sustained growth	Global expansion, broader patient access
2027	$10+	Market maturation	Entry into competitive landscape, patent protections

Revenue growth depends on successful market access, payer acceptance, and ongoing clinical validation. The company anticipates breakeven around 2025 with subsequent profit margins improving as manufacturing scales.

What are the main regulatory and market risks?

Risks include:

• Delays or refusals in full approval based on ongoing trial results.
• Payer restrictions limiting patient access.
• Competitive entrants or better-performing pipeline drugs.
• Manufacturing capacity shortfalls impacting supply.

Regulatory bodies may require post-marketing studies to confirm clinical benefits, which could alter market dynamics.

---

Key Takeaways

• NEURACEQ's initial regulatory approval positions it as a first-in-class disease-modifying therapy for early Alzheimer's.
• Market penetration hinges on clinical data, reimbursement strategies, and supply chain scalability.
• Revenue projections show rapid growth, reaching over $10 billion globally by 2027.
• Competition and technological innovations, especially in diagnostics, will influence NEURACEQ's long-term success.
• Risks involve regulatory uncertainties, payer barriers, and manufacturing bottlenecks.

---

Frequently Asked Questions

1. What clinical benefits are expected from NEURACEQ?
The drug aims to slow cognitive decline by reducing amyloid beta plaques. Confirming improvements in cognition and daily function awaits data from ongoing phase 3 trials.

2. When will NEURACEQ be available outside the U.S.?
European approval is expected within 12 months, subject to EMA review. Other markets will follow depending on local regulatory processes.

3. How will pricing impact access in different markets?
High annual costs may limit initial access to healthcare systems willing to reimburse high-price therapies. Cost-effectiveness analyses will shape coverage decisions.

4. What is the pipeline status of competing treatments?
Lilly’s donanemab and Roche’s gantenerumab are in late-stage trials, potentially providing alternative options for the same patient population.

5. What role will diagnostics play in NEURACEQ’s adoption?
Blood-based amyloid biomarkers will facilitate patient screening and monitoring, easing the treatment pathway and expanding market reach.

---

References

[1] U.S. Food and Drug Administration. (2023). FDA approves lecanemab for early Alzheimer’s disease.
[2] European Medicines Agency. (2023). Lecanemab - pending approval decision.
[3] Biopharma Market Report. (2023). Alzheimer’s disease therapeutics market forecast.
[4] IQVIA. (2023). Global Alzheimer’s market analysis and pipeline overview.